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Nicotiana benthamianaRabies causes more than 60,000 human deaths annually in areas where the virus is endemic. Importantly,
rabies is one of the few pathogens for which there is no treatment following the onset of clinical disease
with the outcome of infection being death in almost 100% of cases. Whilst vaccination, and the combina-
tion of vaccine and rabies immunoglobulin treatment for post-exposure administration are available, no
tools have been identified that can reduce or prevent rabies virus replication once clinical disease has ini-
tiated. The search for effective antiviral molecules to treat those that have already developed clinical dis-
ease associated with rabies virus infection is considered one of the most important goals in rabies
research. The current study assesses a single chain antibody molecule (ScFv) based on a monoclonal anti-
body that potently neutralises rabies in vitro as a potential therapeutic candidate. The recombinant ScFv
was generated in Nicotiana benthamiana by transient expression, and was chemically conjugated (ScFv/
RVG) to a 29 amino acid peptide, specific for nicotinic acetylcholine receptor (nAchR) binding in the
CNS. This conjugated molecule was able to bind nAchR in vitro and enter neuronal cells more efficiently
than ScFv. The ability of the ScFv/RVG to neutralise virus in vivo was assessed using a staggered admin-
istration where the molecule was inoculated either four hours before, two days after or four days after
infection. The ScFv/RVG conjugate was evaluated in direct comparison with HRIG and a potential antiviral
molecule, Favipiravir (also known as T-705) to indicate whether there was greater bioavailability of the
ScFv in the brains of treated mice. The study indicated that the approach taken with the ScFv/RVG con-
jugate may have utility in the design and implementation of novel tools targetting rabies virus infection
in the brain.
 2018 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Rabies is a neglected disease caused by Rabies virus (RABV) that
affects people in many countries, mostly in Asia and Africa. RABV is
a non-segmented negative strand RNA virus in the order Monone-
gavirales, family Rhabdoviridae, genus lyssavirus [1]. Rhabdoviruses
are enveloped with a typical bullet- or rod-shaped morphology and
characterized by an extremely broad host spectrum ranging from
plants to insects to mammals. The genome encodes five proteins
including nucleoprotein, phosphoprotein, matrix protein, glyco-
protein, and RNA polymerase.RABV is almost always transmitted following a bite injury from
an infected animal that is excreting virus in its saliva. The mecha-
nism of virus infection once it has crossed the dermal barrier is
poorly defined. Lyssaviruses are strongly neurotrophic, however,
replication in the musculature, prior to entry into the peripheral
nervous system occurs, and is likely to contribute to the variation
in incubation times seen following infection [2]. Whilst the pro-
drome generally lasts for 3–10 weeks, significantly longer incuba-
tion periods have been reported [3]. Regardless, it is during the
phase between virus replication in the non-neuronal periphery
and movement into the peripheral nervous system that post expo-
sure immunoprophylaxis is hypothesised to be most effective [4].
Current options for rabies post exposure treatment include
immunoprohylaxis with human or equine rabies immunoglobulin
(H/ERIG) at the site of the infection and vaccination at a site distantpotent
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interfere with the humoral immune response [5]. Rabies post-
exposure prophylaxis (PEP) is highly effective if administered in
a timely manner following exposure [6–9]. However, in endemic
regions, knowledge of the most effective actions to take following
an exposure event is often limited, as is the availability of PEP. Fur-
thermore, in remote areas, travel to medical centres for treatment
can delay treatment. If clinical disease develops, PEP is entirely
ineffective [10–12]. Rabies virus antibodies, such as RIG are unli-
kely to offer therapeutic benefits once rabies virus (RABV) has
entered the CNS, as they cannot cross the blood brain barrier
(BBB), a dense cellular network that extends along all capillaries
and consists of tight junctions of endothelial cells that prevent
the entry of large bacterial pathogens and molecules into the
cerebrospinal fluid. The size exclusion limit is approximately
10 kD [13].
Rabies glycoprotein (G), present as a trimeric peplomer on the
viral envelope, contains a short conserved motif which serves to
bind cellular receptors [14], including nicotinic acetylcholine
receptors (nAchRs), to mediate entry into cells [15]. Prior to the
establishment of a productive infection of the CNS, RABV utilises
nAchRs [16] to enter both muscle and nerve cells in the periphery
[17–20]. The identification of a key 29 amino acid peptide in G
responsible for binding and entry into neuronal cells led to the
demonstration that other molecules (siRNA) [21], nanoparticles
[22,23], and enzymes [24,25]] could be delivered to the CNS if
linked to this peptide.
Previous studies have described the application of monoclonal
antibody preparations as an alternative to RIG [26], generation of
monoclonal antibodies in planta and expression of a single chain
antibody fragment (ScFv) of a previously defined rabies neutralis-
ing monoclonal antibody in E. coli [27] and N. benthamiana [28].
In the latter study, a fusion protein comprising ScFv linked to the
RVG peptide at its C-terminus was expressed and shown to neu-
tralise RABV, bind to nAchR and transport across a model BBB.
However, ScFv-RVG fusion was poorly expressed, so although
promising, this strategy was not deemed feasible for further devel-
opment. In the current study, the ScFv was expressed also in N.
benthamiana but chemically conjugated to synthetic 29 amino acid
peptide (ScFv/RVG) for evaluation. The ScFv/RVG conjugate
retained the ability to neutralise RABV. In comparison to ScFv
alone, ScFv/RVG demonstrated enhanced ability to cross an
in vivo 3D cell culture BBB model via a mechanism that involves
the N-acetylcholine receptor. Finally, the ability of ScFv/RVG to
act as a potential post-exposure tool was assessed in vivo. Direct
in vivo comparisons with the action of HRIG demonstrated that
ScFv/RVG may have future utility as a post-exposure alternative
to HRIG for rabies virus post exposure treatment.
2. Materials and methods
2.1. ScFv and ScFv/RVG production
The pEAQ-62-71-3 IgG [27] and the pEAQ-ScFv vectors used for
expression of recombinant antibodies have been described previ-
ously [29]. Agrobacterium tumefaciens LBA4404 was separately
transformed with the pEAQ-62-71-3 IgG [27] and the pEAQ-ScFV
[28] vectors by electroporation. The resulting recombinant bacte-
rial strains were verified by restriction digest of plasmids, grown
overnight at 28 C and used to infiltrate leaves of 6–8 week-old
greenhouse-grown N. benthamiana plants, by vacuum infiltration
as described [30]. The recombinant plant expressed antibodies
were extracted in 3 volumes of PBS (pH7.4) and purified by Ni-
affinity chromatography [28]. 10 mg of ScFv (MW = 56 kDa) and
the linker (succinimidyl-4-formylbenzamide) were dissolved in
PBS. The linker solution was added to the ScFv solution under stir-Please cite this article in press as: Phoolcharoen W et al. In vitro and in vivo eval
rabies neutralisation activity. Vaccine (2018), https://doi.org/10.1016/j.vaccinering, and the solution was agitated for 30 min in room tempera-
ture. The RVG peptide was synthesized by Pepscan (Lelystad, The
Netherlands). 10 mg of the peptide (MW = 3 kDa) was dissolved
in water and adjusted to pH7 with PBS. After the linker/ScFv solu-
tion was dialyzed in PBS for 15 min 4 times, it was added to the
peptide solution under stirring at room temperature. After 2 h,
the protein was dialyzed in PBS overnight. The reaction feed was
50% peptide and 50% ScFv, and the molar ratio was 18:1.
2.2. SDS-PAGE and western blot
Crude protein extracts from plant leaves were prepared 5 days
after agro-infiltration and denatured by boiling in NuPAGE LDS
Sample Buffer. Proteins were separated on 4–12% gradient poly-
acrylamide gels (Life Technologies, UK). Proteins were visualised
by Coomasie staining, or electrophoretically transferred to a nitro-
cellulose membrane for immunoblotting. Nitro-cellulose mem-
branes were blocked (5% non-fat dried milk, 0.1% Tween20 in
PBS) before being probed with horseradish peroxidase (HRP) con-
jugated mouse anti-E-tag antiserum (Abcam, UK) diluted at
1:5000 in 1% non-fat dried milk in PBST. Bands were visualised fol-
lowing addition of ECL plus detection reagent (GE Healthcare, UK).
2.3. Cells and viruses
Human embryonic kidney 293 cells expressing human a7-
nicotinic acetylcholine receptor (HEKnAchR7) were reported previ-
ously [31]. The immortalized human brain capillary endothelial
cell line (hCMEC/D3) [32] was purchased from Tebu Bio (France)
and the cells were grown according to the manufacturer’s instruc-
tion. Silver Haired Bat rabies variant (SHBV) [33] was used for the
rabies virus pathogenicity experiments.
2.4. nAchR binding and competition assay
HEK 293 cells or Neuroscreen-1 (Thermo-Fisher, UK) cells were
seeded on 6-well plates. After 24 h, cells were placed on ice and
incubated with ScFv or ScFv/RVG for 5 min (binding assay) or 30
min (entry assay). The cells were washed with PBS, then harvested
into FACS tubes and incubated in cell fixation solution (BD Bio-
sciences, USA) for 15 min. For the binding assay, samples were
washed 3 times with 1% inactivated foetal calf serum (0.1% NaN3)
in PBS, pH 7.4. For the entry assay, samples were washed 3 times
with permeabilization buffer (1% inactivated fetal calf serum,
0.1% NaN3, and 0.1% Saponin in PBS, pH 7.4) before the cells were
incubated with 1:1000 mouse anti-E tag antiserum at 4 C, over-
night. The cells were then washed as before, before incubation
with a goat anti-mouse IgG antiserum conjugated with cy5 (Jack-
son laboratory, USA) at 37 C for 1 h. After further washing, the
cells were resuspended in staining buffer and analysed by flow
cytometry, using FACS CellQuest software (BD Biosciences, USA).
For the competition assay, cells were pretreated on ice with either
2  107 PFU of UV inactivated Rabies virus (CVS) [34] or 16 lM
alpha bungarotoxin (Tocris Bioscience, UK) for 30 min, before the
ScFv or ScFv/RVG conjugate was added. The binding and competi-
tion assays were analyzed in three independent experiments.
2.5. In vitro BBB transwell assay
An immortalized human brain capillary endothelial cell line
(hCMEC/D3) was kindly provided by Prof. Pierre-Olivier Couraud
(Institut Cochin, Université René Descartes, Paris, France) and Prof.
Pierre-Emmanuel Ceccaldi (Institut Pasteur, Paris) [35]. Cells were
seeded on the apical side of a Cultrex Rat Collagen I (150 lg/ml;
R&D Systems, USA) coated 0.9 cm2 polyethylene terephthalate fil-
ter insert with 3.0 lm porosity (BD Falcon, UK). The restrictiveuation of a single chain antibody fragment generated in planta with potent
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low permeability to the non-permeant fluorescent marker Lucifer
Yellow (LY) [29]. 10 mg of antibody preparation was added to the
top chamber and the cells were incubated (37 C; 5% CO2) and sam-
ples were taken after 2 h and 18 h to assess the media in the bot-
tom chamber for the presence of antibody by virus neutralisation.
2.6. In vivo assessment of ScFV/RVG
All in vivo work was undertaken in BSL3/SAPO4 containment at
the Animal and Plant Health Agency (APHA), following indepen-
dent ethical review under strict Home Office guidelines
(PPL70/7394). Molecules were administered to groups of mice by
intraperitoneal inoculation. Intra-peritoneal administration (IP) of
ScFv/RVG was compared to treatment with human rabies
immunoglobulin (HRIG) as both a pre- and post-exposure treat-
ment. Treatments with Favipiravir (T-705, a broad-spectrum RNA
polymerase inhibitor), and T-705 with ScFv/RVG were also
included in the study.
Mice (n = 12/group) received ScFv/RVG (40 IU/kg), HRIG (40 IU/
kg), T-705 (300 mg/kg) or ScFv/RVG (40 IU/kg) + T-705 (300 mg/
kg) or were controls receiving PBS following the same treatment
schedule. Mice were tagged and numbered before using a random
number generator to distribute mice into groups. Each group of 12
mice was randomly split across two boxes of 6 mice each, to take
account of interactions among mice sharing boxes and any other
differences between boxes. Groups of mice were treated for 10
consecutive days. The treatments were initiated either four hours
before virus inoculation (4hr), two days (+2d) after virus infec-
tion or 4 days (+4d) after virus inoculation. Virus used for inocula-
tion was a bat rabies strain originally isolated from a human
fatality following infection from an insectivorous bat [36]. Mice
were challenged with 50 ml RABV at 105.8 TCID50/ml by intra-
muscular injection into the left hind leg. Mice were weighed daily
during the 10 day treatment period to determine both weight loss
due to infection and assign any possible adverse effect of treatment
with ScFv, T705 or HRIG. Animals were monitored for 54 days and
any deaths were recorded.
The data were analysed for treatment effects as a factorial
design (5 treatments  3 timings) by applying a multilevel mixed
effects logistic regression to take account of potential correlation
among mice in each box (melogit in Stata 14, treating differences
between boxes as random effects). Treatment effects were calcu-
lated as logits of mortality, where a logit is the logarithm of the
odds ratio logitðpÞ ¼ loge p1p
  
. Treatments were compared
using their logits: the treatment with higher logit results in higher
mortality. A difference of zero indicates that two treatments have
the same effect, a difference of 1.0 is equivalent to increasing mor-
tality from 0.5 to 0.731, while a difference of 1.0 would be equiv-
alent to reducing mortality from 0.731 to 0.5. The generalised
linear statistical model assumed that the effect of combined treat-
ments can be predicted by adding their effects on the logit scale.
Deviation from this prediction indicates that the treatments inter-
act. The model estimated standard errors for the differences
between treatments, which allowed calculation of 95% confidence
intervals and testing against a null hypothesis that the treatment
effects were equal.
3. Results
3.1. Characterisation of the 62-71-3 ScFv and the ScFv/RVG conjugate
The purified ScFv and the ScFv/RVG conjugate were assessed by
SDS-PAGE gel followed by Coomassie staining (Fig. 1A) or by
immunoblotting with horseradish peroxidase conjugated mousePlease cite this article in press as: Phoolcharoen W et al. In vitro and in vivo eval
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inantly at approximately 56 kDa, which was the major band
detected. ScFv/RVG migrated slightly slower than ScFv as expected
and the slight smearing of this band is consistent with variable
levels of RVG peptide conjugation. Again, this band is the major
component of the preparation. Higher molecular weight bands
(approximately 150 kDa) are likely to represent ScFv aggregates,
whilst lower molecular weight bands (30–35 kDa) are likely to rep-
resent ScFv degradation products. The identity of the bands was
supported by western blot (Fig. 1B).
3.2. Neutralization of rabies virus
The parent monoclonal antibody (62-71-3) and two versions of
ScFv were tested to determine their capability to neutralize rabies
virus (ERA strain) using a plaque-inhibition assay. The starting con-
centrations for all three antibodies was 0.5 mg/ml and the results
suggest that the neutralizing activity of ScFv and ScFv/RVG conju-
gate was not significantly different to that of 62-71-3 mAb (Fig. 2).
3.3. Binding to nAchR and cell entry
The binding and penetration of ScFv and ScFv/RVG conjugate in
HEK 293 cells overexpressing nAchR were tested by flow cytome-
try. A greater proportion of ScFv/RVG bound to the 293 cells as evi-
denced by the shift to the right of the dotted line compared to ScFv
(solid line) (Fig. 3A). After a longer incubation (30 min) a greater
amount of ScFv/RVG was associated with the 293 cells compared
to ScFv (Fig. 3B), and this represents ScFv that has entered the tar-
get cells.
The specificity of binding between ScFv/RVG and HEK 293 cells
via nAchR was tested by a competitive assay using irradiated rabies
virus and a-bungarotoxin. The HEK 293 cell line was pre-incubated
with each inhibitor, before incubation with ScFv or ScFv/RVG. No
effect of either irradiated virus or a-bungarotoxin was observed
in the case of ScFv (Fig. 4A and C, respectively). However, for
ScFv/RVG there was a shift, with less ScFv/RVG detected within
the cells in the presence of both inhibitors (Fig. 4B and D, respec-
tively). The assays were repeated using Neuroscreen-1 cells, a
model neuronal cell line, with identical results (Fig. 4E–H).
3.4. Passage of ScFv/RVG conjugate across an in vitro model of the
blood brain barrier
An in vitro BBB transport experiment was conducted on an
hCMEC/D3 cell monolayer as described previously [35]. After addi-
tion of antibodies to the upper chamber, the media in the lower
chamber was tested for rabies virus neutralizing activity after incu-
bation periods of 2 and 18 h (Fig. 5). No evidence for the ability of
full length 62-71-3 mAb to cross the cell monolayer was found.
This is consistent with previous reports [28,37] and demonstrates
the integrity of the monolayer. Similarly, a 62-71-3 IgG/RVG conju-
gate was also unable to cross the monolayer. There was some
detectable ScFv in the bottom chamber at both time points, but
as the levels were similar at both time points, we interpret this
to represent slight leakage of the monolayer to small proteins. In
contrast, a greater amount of ScFv/RVG passed through the
hCMEC/D3 cells, and the concentration of ScFv/RVG as measured
by virus neutralising activity of the media in the bottom well
increased approximately 100-fold after 18hr incubation (Fig. 5).
3.5. In vivo assessment of ScFv/RVG
The effectiveness of the ScFv/RVG conjugate against rabies viral
challenge was assessed in vivo. There was a clear trend showing
greatest mortality in PBS treated groups, compared with thoseuation of a single chain antibody fragment generated in planta with potent
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Fig. 1. Characterisation of ScFv and ScFv/RVG conjugate. The plant-produced ScFv
was purified by Ni affinity chromatography. The ScFv was chemically conjugated to
chemically synthesized RVG peptide to produce ScFv/RVG. ScFv and ScFv/RVG
conjugate were analysed by SDS-PAGE under reducing conditions, followed by (A)
staining with Coomassie blue or (B) blotting onto nitrocellulose and probing with a
mouse anti-E tag antiserum. (For interpretation of the references to colour in this
figure legend, the reader is referred to the web version of this article.)
ScFv/RVG 
ScFv 
IgG-62-71-3 
Fig. 2. Rabies virus (ERA stain) neutralization by ScFv and ScFv/RVG conjugate
compared with 62-71-3 mAb IgG antibody as assessed by RFFIT on BSR cells.
Antibody starting concentrations were 0.5 mg/ml. Assays were performed in
triplicate. Error bars indicate the SD.
4 W. Phoolcharoen et al. / Vaccine xxx (2018) xxx–xxxtreated with HRIG (lowest) and ScFv/RVG (Figs. 6, 7). Unexpect-
edly, even 4 days after viral challenge, HRIG was almost totally
protective, and there was no evidence of any effect from the timing
of treatments. Among the four treatments ScFv/RVG, T-705, ScFv/
RVG with T-705 and HRIG, the estimated effect on logit mortality
from treating at 2d relative to 4h = 0 (95% confidence interval
1.08 to 1.08); 4d relative to 4h = 0.16 (1.26 to 0.94). T705
reduced mortality to a similar degree compared with ScFv/RVG
(Figs. 6B, 7), and the group treated with the combination of ScFv/
RVG conjugate with T-705 reduced mortality to a level similar toPlease cite this article in press as: Phoolcharoen W et al. In vitro and in vivo eval
rabies neutralisation activity. Vaccine (2018), https://doi.org/10.1016/j.vaccineHRIG (Fig. 6B, 7). However, although the best model of the exper-
imental observations was that the effects of T705 and ScFv/RVG
were additive, the difference between T705 alone and the combi-
nation of T705 with ScFv/RVG conjugate did not reach the thresh-
old for statistical significance at P < 0.05 (Fig. 7).4. Discussion
The blood-brain barrier remains a major bottleneck for drug
development, for rabies and many other brain diseases. Several
strategies have been developed, including the use of nanotechnol-
ogy employing liposomes [38], polymeric nanoparticles [39],
micelles [40], gold particles [41], etc. Another strategy is the use
of antibodies to target receptors on the surface of endothelial cells
allowing transport of drugs into the brain. Examples include anti-
bodies against the transferrin receptor [42–44], insulin receptor
[45,46] or the low density lipoprotein receptor [47]. Peptides have
also gained attention for their potential to mediate delivery across
the BBB [48–50]. The rabies virus glycoprotein (RVG) peptide used
in this study binds specifically to the acetylcholine receptor
(nAchR) expressed on neuronal cells. Several studies have demon-
strated that RVG peptide can deliver siRNA [21] and proteins
[22,51] through the BBB.
Our previous work demonstrated expression of a ScFv version of
the rabies neutralising monoclonal antibody 62-71-3 in planta [27].
The lyssavirus neutralisation activity of the ScFv was equivalent to
that of the IgG parent antibody. In a preliminary study, an ScFv-
RVG fusion protein was engineered, and we were able to demon-
strate some of the functional characteristics of this molecule
[28]. However, the expression level of this molecule in plants
was extremely low, approximately 2 mg/kg fresh leaf weight,
which is significantly below the level required for commercial via-
bility. By comparison, IgG antibodies are currently being developed
that express in Nicotiana in the range of 100 mg/kg fresh leaf
weight [52].
In this study, our strategy was to express the 62-71-3 ScFv
molecule separately in Nicotiana benthamiana and following
purification, use chemical conjugation to synthetic RVG peptide.
The ScFv was expressed at 35–50 mg/kg fresh leaf weight which
has important advantages in terms of downstream processing
and purification, and consequently on commercial viability.
Chemical conjugation of RVG peptide to ScFv is also potentially
advantageous because multiple peptides could be attached to a
single ScFv molecule, thereby increasing affinity for the nAchR.
Indeed, as shown in the SDS-PAGE and western blot of the
ScFv/RVG conjugate, the product band indicates molecules with
a range of sizes.
Importantly, RVG conjugation did not affect rabies neutralisa-
tion activity, and there was no discernible difference between
unconjugated ScFv and ScFv/RVG. The ScFv/RVG conjugate did
mediate binding and entry into cells overexpressing nAchR and a
neuron-like cell line (neuroscreen cells) and the role of nAchR in
this interaction was demonstrated by the ability of both rabies
virus and alpha-bungarotoxin to competitively inhibit ScFv.
Alpha-bungarotoxin is a neurotoxin that binds nAchR at the same
site as rabies glycoprotein [53].
An in vitromodel was utilised to investigate the potential trans-
port of different antibody based molecules across the blood brain
barrier. This model was impermeable to the full length 62-71-3
IgG mAb as expected. Conjugating RVG to 62-71-3 IgG made no
difference, indicating that that the size of IgG is a limiting factor.
Although there was some apparent passage of ScFv across the
BBB model, this was significantly enhanced in the case of ScFv/
RVG. The increasing concentration of neutralising activity in the
lower chamber of this assay with time, in comparison with theuation of a single chain antibody fragment generated in planta with potent
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Fig. 3. Binding and entry of 62-71-3 ScFv to 293 cells overexpressing nAchR by flow cytometry. Binding (A) and entry (B) were detected with mouse anti-E antiserum and cy5
conjugated goat anti-mouse IgG antiserum, Solid line: ScFv, Dotted line: ScFv/RVG conjugate. A representative result from triplicate experiments is shown.
A B
C D
E F
G H
ScFv   ScFv/RVG 
  UV-RABV 
  α-bungarotoxin 
  UV-RABV 
  α-bungarotoxin 
  293 cells  
overexpressed nAchR 
Neuroscreen cells 
Fig. 4. Inhibition of entry of ScFv/RVG conjugate into nAchR-overexpressing 293 cells and neuroscreen cells by irradiated rabies virus and a-bungarotoxin. Flow cytometry on
nAchR-overexpressing 293 cells pre-treated with irradiated rabies virus (A, B) and a-bungarotoxin (C, D) before incubation with ScFv (A and C), and ScFv/RVG conjugate (B
and D). Flow cytometry on neuronal 2a cells pre-treated with irradiated rabies virus (E, F) and a-bungarotoxin (G, H) before incubation with ScFv (E and G) and ScFv/RVG
conjugate (F and H). Solid line: no inhibitor, Dotted line: pre-treated with irradiated rabies virus or a-bungarotoxin; A representative result from triplicate experiments is
shown.
W. Phoolcharoen et al. / Vaccine xxx (2018) xxx–xxx 5result using unconjugated ScFv alone, suggests that transport was
mediated by an active mechanism.
An in vivo assessment of ScFv/RVG was subsequently attempted
using a murine model of rabies virus infection and different treat-
ment schedules with either HRIG or the ScFv molecule. For this
experiment, treatment schedules were designed on the hypothesisPlease cite this article in press as: Phoolcharoen W et al. In vitro and in vivo eval
rabies neutralisation activity. Vaccine (2018), https://doi.org/10.1016/j.vaccinethat at 4 h before inoculation and 2 days post inoculation, the
infecting virus would still be in the periphery and that an estab-
lished neuronal infection had not yet been initiated. The 4 day post
inoculation treatment schedule was chosen because it was
expected that an infection of the central nervous system would
have established, so it should be possible to demonstrateuation of a single chain antibody fragment generated in planta with potent
.2018.02.057
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Fig. 5. ScFv/RVG conjugate transports across in vitro BBB model. 10 lg antibodies
were added to the upper chamber of hCMEC/D3 cells in the transwell. Media in the
bottom well was tested for rabies virus neutralization assay after 2 and 18 h. A
representative result from triplicate experiments is shown.
6 W. Phoolcharoen et al. / Vaccine xxx (2018) xxx–xxxprotective efficacy from ScFv/RVG due to greater accessibility to
the brain [54].
However, the results suggest that the virus took longer to reach
the CNS than expected. HRIG was protective when delivered at all
time points, even though it is well established that HRIG does not
provide protection once rabies virus infection enters the CNS. So0
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Fig. 6. (a) Mouse survival curves for the three treatments ScFv/RVG, HRIG and PBS only
Mouse survival curves for the five treatments ScFv/RVG, T-705, ScFv/RVG with T-705, H
which did not significantly affect treatment effects.
Please cite this article in press as: Phoolcharoen W et al. In vitro and in vivo eval
rabies neutralisation activity. Vaccine (2018), https://doi.org/10.1016/j.vaccineunfortunately, no conclusions can be drawn regarding potential
ScFv mediated protection within the CNS. With no significant effect
from the timing of treatments, ScFv/RVG halved mortality relative
to the control treatment, but did not match the 90% protection
observed for HRIG. Although the dosages administered were equiv-
alent in terms of International Units/kg, ScFv/RVG performed less
effectively than HRIG. This is likely to be due to different pharma-
cokinetics, as without Fc, ScFv/RVG would be expected to have a
shorter serum half life [55]. Favipiravir (T705) performed similarly
to ScFv/RVG. However, the combination of ScFv/RVG with T-705
appeared to match the protection from HRIG, most likely because
the effects of ScFv/FVG and T-705 were additive, but the evidence
is not decisive. The relative performance of ScFv/RVG and HRIG
when treatment is sufficiently delayed for mortality to be high with
HRIG treatment remains unknown. This study did however, con-
firm the protective property of ScFv/RVG in vivo, and demonstrates
that the chemical conjugation process does not affect the viral neu-
tralisation properties of the ScFv in vivo. A definitive pre-clinical
study demonstrating protective efficacy in a robust model for cen-
tral nervous system infection by rabies virus is now required.
In conclusion, the adaptation of ScFv through conjugation to a
29 amino acid RVG peptide has enabled greater bioavailability of
the molecule. In particular, the approach adopted in this study
overcomes the problem of low yield, and the scalable production
of rabies ScFv molecule in plants is promising. RVG peptide synthe-
sis and the conjugation process are readily available commerciallyHRIG -4h
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This leads to the possibility for rapid large scale production of the
conjugated molecule and relatively quick translation to clinical
trial. The development and clinical evaluation of new tools for post
exposure control for rabies virus infection in endemic areas is a
matter of some urgency.
Acknowledgements
This work was supported by the Royal Society (Newton Interna-
tional fellowship to W. Phoolcharoen), a Wellcome Trust grant
(WT093092MA), the Hotung Foundation and an ERC award (ERC-
2010-AdG_20100317). The studies undertaken at APHA received
partial financial support from the EU FP7 project (ASKLEPIOS
602825) and by the UK Department for Environment, Food and
Rural Affairs (Defra projects SE0426 and SE0431).
References
[1] Dietzgen RG, et al., Family rhabdoviridae. In: King AMQ, et al., editors. Virus
taxonomy: ninth report of the international committee on taxonomy of
viruses. 2011 Elsevier Academic Press. p. 686–714.
[2] Schnell MJ et al. The cell biology of rabies virus: using stealth to reach the
brain. Nat Rev Microbiol 2010;8(1):51–61.
[3] Johnson N, Fooks A, McColl K. Human rabies case with long incubation,
Australia. Emerging Infect Diseases 2008;14(12):1950–1.
[4] WHO, WHO Expert Consultation on Rabies, in World Health Organ Tech Rep
Ser WHO, Editor. 2013. p. 1–139.
[5] Both L et al. Passive immunity in the prevention of rabies. Lancet Infect Dis
2012;12(5):397–407.
[6] Shantavasinkul P, Wilde H. Postexposure prophylaxis for rabies in resource-
limited/poor countries. Adv Virus Res 2011;79:291–307.
[7] Uwanyiligira M et al. Rabies postexposure prophylaxis in routine practice in
view of the new Centers for Disease Control and Prevention and World Health
Organization recommendations. Clin Infect Dis 2012;55(2):201–5.
[8] Hemachudha T, Laothamatas J, Rupprecht CE. Human rabies: a disease of
complex neuropathogenetic mechanisms and diagnostic challenges. Lancet
Neurol 2002;1(2):101–9.
[9] Lewis P, Fu Y, Lentz TL. Rabies virus entry at the neuromuscular junction in
nerve-muscle cocultures. Muscle Nerve 2000;23(5):720–30.
[10] Kaplan MM et al. Studies on the local treatment of Wounds for the prevention
of rabies. Bull WHO 1962;26:765–75.
[11] Hanlon CA et al. The incurable wound revisited: progress in human rabies
prevention? Vaccine 2001;19(17–19):2273–9.
[12] Fangtao L et al. Use of serum and vaccine in combination for prophylaxis
following exposure to rabies. Rev Infect Dis 1988;10(4):S766–70.
[13] Pardridge WM. Biopharmaceutical drug targeting to the brain. J Drug Target
2010;18(3):157–67.
[14] Lafon M. Rabies virus receptors. J Neurovirol 2005;11(1):82–7.
[15] Lafon M. Rabies virus superantigen. Res Immunol 1993;144(3):209–13.
[16] Lentz TL et al. Synthetic peptides in the study of the interaction of rabies virus
and the acetylcholine receptor. Adv Biochem Psychopharmacol
1988;44:57–71.Please cite this article in press as: Phoolcharoen W et al. In vitro and in vivo eval
rabies neutralisation activity. Vaccine (2018), https://doi.org/10.1016/j.vaccine[17] Lentz TL et al. Is the acetylcholine receptor a rabies virus receptor? Science
1982;215(4529):182–4.
[18] Burrage TG, Tignor GH, Smith AL. Rabies virus binding at neuromuscular
junctions. Virus Res 1985;2(3):273–89.
[19] Lentz TL, Hawrot E, Wilson PT. Synthetic peptides corresponding to sequences
of snake venom neurotoxins and rabies virus glycoprotein bind to the nicotinic
acetylcholine receptor. Proteins 1987;2(4):298–307.
[20] Lentz TL. Rabies virus binding to an acetylcholine receptor alpha-subunit
peptide. J Mol Recognit 1990;3(2):82–8.
[21] Kumar P et al. Transvascular delivery of small interfering RNA to the central
nervous system. Nature 2007;448(7149):39–43.
[22] Kim JY et al. Brain-targeted delivery of protein using chitosan- and RVG
peptide-conjugated, pluronic-based nano-carrier. Biomaterials 2013;34
(4):1170–8.
[23] Hwang do W, et al. A brain-targeted rabies virus glycoprotein-disulfide linked
PEI nanocarrier for delivery of neurogenic microRNA. Biomaterials 2011; 32
(21): 4968–75.
[24] Xiang L et al. Targeted delivery of large fusion protein into hippocampal
neurons by systemic administration. J Drug Target 2011;19(8):632–6.
[25] Fu A et al. Targeted delivery of proteins into the central nervous system
mediated by rabies virus glycoprotein-derived peptide. Pharm Res 2012;29
(6):1562–9.
[26] Muller T et al. Development of a mouse monoclonal antibody cocktail for
post-exposure rabies prophylaxis in humans. PLoS Negl Trop Dis 2009;3(11):
e542.
[27] Both L et al. Production, characterization, and antigen specificity of
recombinant 62–71-3, a candidate monoclonal antibody for rabies
prophylaxis in humans. FASEB J 2013;27(5):2055–65.
[28] Phoolcharoen W et al. Enhanced transport of plant-produced rabies single-
chain antibody-RVG peptide fusion protein across an in cellulo blood-brain
barrier device. Plant Biotechnol J 2017.
[29] Phoolcharoen W et al. Enhanced transport of plant-produced rabies single-
chain antibody-RVG peptide fusion protein across an in cellulo blood-brain
barrier device. Plant Biotechnol J 2017;15(10):1331–9.
[30] Huang Z et al. A DNA replicon system for rapid high-level production of virus-
like particles in plants. Biotechnol Bioeng 2009;103(4):706–14.
[31] Yamauchi JG et al. Characterizing ligand-gated ion channel receptors with
genetically encoded Ca2++ sensors. PLoS One 2011;6(1):e16519.
[32] Weksler BB et al. Blood-brain barrier-specific properties of a human adult
brain endothelial cell line. FASEB J 2005;19(13):1872–4.
[33] Thoulouze MI et al. Rabies virus infects mouse and human lymphocytes and
induces apoptosis. J Virol 1997;71(10):7372–80.
[34] Megret F et al. Immunopotentiation of the antibody response against influenza
HA with apoptotic bodies generated by rabies virus G-ERA protein-driven
apoptosis. Vaccine 2005;23(46–47):5342–50.
[35] Eigenmann DE et al. Comparative study of four immortalized human brain
capillary endothelial cell lines, hCMEC/D3, hBMEC, TY10, and BB19, and
optimization of culture conditions, for an in vitro blood-brain barrier model
for drug permeability studies. Fluids Barriers CNS 2013;10(1):33.
[36] Morimoto K et al. Characterization of a unique variant of bat rabies virus
responsible for newly emerging human cases in North America. Proc Natl Acad
Sci United States Am 1996;93(11):5653–8.
[37] Markoutsa E et al. Uptake and permeability studies of BBB-targeting
immunoliposomes using the hCMEC/D3 cell line. Eur J Pharm Biopharm
2011;77(2):265–74.
[38] Rip J. Liposome technologies and drug delivery to the CNS. Drug Discov Today
Technol 2016;20:53–8.
[39] Portioli C et al. Novel functionalization strategies of polymeric nanoparticles as
carriers for brain medications. J Biomed Mater Res A 2017;105(3):847–58.
[40] Meng X et al. Pluronic F127 and D-alpha-Tocopheryl Polyethylene Glycol
Succinate (TPGS) mixed micelles for targeting drug delivery across the blood
brain barrier. Sci Rep 2017;7(1):2964.
[41] Li CH et al. Gold nanoparticles increase endothelial paracellular permeability
by altering components of endothelial tight junctions, and increase blood-
brain barrier permeability in mice. Toxicol Sci 2015;148(1):192–203.
[42] Boado RJ et al. Pharmacokinetics and brain uptake of a genetically engineered
bifunctional fusion antibody targeting the mouse transferrin receptor. Mol
Pharm 2010;7(1):237–44.
[43] Niewoehner J et al. Increased brain penetration and potency of a therapeutic
antibody using a monovalent molecular shuttle. Neuron 2014;81(1):49–60.
[44] Bien-Ly N et al. Transferrin receptor (TfR) trafficking determines brain uptake
of TfR antibody affinity variants. J Exp Med 2014;211(2):233–44.
[45] Pardridge WM et al. Human insulin receptor monoclonal antibody undergoes
high affinity binding to human brain capillaries in vitro and rapid transcytosis
through the blood-brain barrier in vivo in the primate. Pharm Res 1995;12
(6):807–16.
[46] Boado RJ et al. Genetic engineering of a lysosomal enzyme fusion protein for
targeted delivery across the human blood-brain barrier. Biotechnol Bioeng
2008;99(2):475–84.
[47] Tian X et al. LRP-1-mediated intracellular antibody delivery to the Central
Nervous System. Sci Rep 2015;5:11990.
[48] Kristensen M, Brodin B. Routes for drug translocation across the blood-brain
barrier: exploiting peptides as delivery vectors. J Pharm Sci 2017.
[49] Zhang D, Wang J, Xu D. Cell-penetrating peptides as noninvasive
transmembrane vectors for the development of novel multifunctional drug-
delivery systems. J Control Release 2016;229:130–9.uation of a single chain antibody fragment generated in planta with potent
.2018.02.057
8 W. Phoolcharoen et al. / Vaccine xxx (2018) xxx–xxx[50] Velasco-Aguirre C et al. Peptides and proteins used to enhance gold
nanoparticle delivery to the brain: preclinical approaches. Int J
Nanomedicine 2015;10:4919–36.
[51] Zou Z, et al. Cre fused with RVG peptide mediates targeted genome editing in
mouse brain cells in vivo. Int J Mol Sci; 2016 17(12).
[52] Teh AY et al. Characterization of VRC01, a potent and broadly neutralizing
anti-HIV mAb, produced in transiently and stably transformed tobacco. Plant
Biotechnol J 2014;12(3):300–11.Please cite this article in press as: Phoolcharoen W et al. In vitro and in vivo eval
rabies neutralisation activity. Vaccine (2018), https://doi.org/10.1016/j.vaccine[53] Donnelly-Roberts DL, Lentz TL. Synthetic peptides of neurotoxins and rabies
virus glycoprotein behave as antagonists in a functional assay for the
acetylcholine receptor. Pept Res 1989;2(3):221–6.
[54] Warrell MJ. The dilemma of managing human rabies encephalitis. Trop Med
Int Health 2016;21(4):456–7.
[55] Andersen JT et al. Cross-species binding analyses of mouse and human
neonatal Fc receptor show dramatic differences in immunoglobulin G and
albumin binding. J Biol Chem 2010;285(7):4826–36.uation of a single chain antibody fragment generated in planta with potent
.2018.02.057
